OPUS GENETICS INC
IRDNASDAQTrading Snapshot
- Day Range
- $4.91 – $4.99
- 52-Week Range
- $1.50 – $7.07
- Volume
- $3.82B
- Avg Volume
- $4.11B
- Shares Outstanding
- 82.6M
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $755,000
- P/E Ratio
- -3.9
- P/S Ratio
- 41.5x
- EPS (TTM)
- $-1.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1870.6%
Why Investors Own IRD
- ✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OPUS GENETICS INC
IRD
StockOtter · stockotter.spaceAbout OPUS GENETICS INC
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
OPUS GENETICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift IRD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
OPUS GENETICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.